

## Press Release

### **Kraig Biocraft Laboratories, Inc. Announces Dr. Donald Jarvis Has Joined Its Scientific Advisory Board**

*- Renowned Biochemist Who Is Developing Spider Silk Polymers Joins Kraig-*

**LANSING, MI – April 30, 2008 -- Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB)** announced today that renowned genetic researcher, inventor, and the developer of technologies related to pharmaceutical platforms, Dr. Donald Jarvis, has joined the Company's Board of Scientific Advisors.

Dr. Jarvis is very well known in the scientific community for his revolutionary work in genetics and biochemicals. He is the author or coauthor of more than one hundred scientific articles relating to genetic or biochemical engineering. "More importantly," said Kraig's CEO Kim Thompson, "Dr. Jarvis is the inventor or co-inventor of more than a dozen patent applications, including technologies related to pharmaceutical production. It is his developmental work with spider silk polymers which first caught Kraig's attention."

Dr. Jarvis is a member of the faculty at the University of Wyoming, where he heads a research laboratory focused on biochemical technologies. "The University of Wyoming has long been at the forefront of recombinant spider silk technology," said Thompson, "so it is natural that Dr. Jarvis would devote his considerable talents in that area. We are very fortunate and excited to have him on our team."

Dr. Jarvis is the second member of the University's faculty to join Kraig. Kraig is working to develop and commercialize high performance polymers using spider silk gene sequences discovered and invented at the University of Wyoming. The company hopes to tap into the \$92 billion market for high performance and technical fibers. In 2006 Kraig Biocraft Laboratories signed an intellectual property licensing agreement with the University of Wyoming. At that time the University of Wyoming Foundation became a major shareholder in the Company.

For more information on Kraig Biocraft Laboratories, and to hear an audio interview with Kraig's CEO, please visit the Company's web site: [www.KraigLabs.com](http://www.KraigLabs.com)

Statements in this press release about the company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "hopes," "develops", "researching," "research," "could" or other words or phrases of similar import. Similarly, statements in this release that describe the Company's business strategy, outlook, objectives, plans, intentions or goals should all be considered forward-looking statements. All such forward-looking statements are subject

to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. Management cautions that its ability to further its research, and create commercially-viable products may be affected by the competitive environment, the Company's financial condition and its ability to raise sufficient capital to meet the financial obligations of its business plan and to fund its continuing operations.

Contact:

Kraig Biocraft Laboratories, Inc.

Kim Thompson CEO

(517) 336-0807

[info@KraigLabs.com](mailto:info@KraigLabs.com)